Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Ten Haaf

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Cancer|February 28, 2019
Treatment capacity required for full-scale implementation of lung cancer screening in the United StatesErik F Blom, Kevin Ten Haaf, Douglas A Arenberg, et al.
Annals of the American Thoracic Society|November 2, 2019
Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United StatesErik F Blom, Kevin Ten Haaf, Douglas A Arenberg, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2024
Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021)Koen de Nijs, Harry J de Koning, Carlijn van der Aalst, et al.
Eclinicalmedicine|May 30, 2024
Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the NetherlandsKoen de Nijs, Kevin Ten Haaf, Carlijn van der Aalst, et al.
International Journal of Cancer|October 4, 2023
Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in SwitzerlandYuki Tomonaga, Koen de Nijs, Heiner C Bucher, et al.
International Journal of Cancer|March 30, 2021
Personalising lung cancer screening: An overview of risk-stratification opportunities and challengesKevin Ten Haaf, Carlijn M van der Aalst, Harry J de Koning, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2015
Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening StudyUraujh Yousaf-Khan, Nanda Horeweg, Carlijn van der Aalst, et al.
Journal of the National Cancer Institute|November 9, 2017
Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the MethodologyTheodora M Ripping, Kevin Ten Haaf, André L M Verbeek, et al.
The Lancet Regional Health. Western Pacific|December 10, 2024
Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for AustraliaJacqueline Roseleur, Jonathan Karnon, Harry de Koning, et al.
Cancer|November 1, 2023
Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling studyRafael Meza, Pianpian Cao, Koen de Nijs, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Cancer|February 28, 2019
Treatment capacity required for full-scale implementation of lung cancer screening in the United StatesErik F Blom, Kevin Ten Haaf, Douglas A Arenberg, et al.
Annals of the American Thoracic Society|November 2, 2019
Disparities in Receiving Guideline-Concordant Treatment for Lung Cancer in the United StatesErik F Blom, Kevin Ten Haaf, Douglas A Arenberg, et al.
European Journal of Cancer (Oxford, England : 1990)|July 24, 2024
Medical costs of lung cancer by stage, histology and first-line treatment modality in the Netherlands (2012-2021)Koen de Nijs, Harry J de Koning, Carlijn van der Aalst, et al.
Eclinicalmedicine|May 30, 2024
Projected effectiveness of lung cancer screening and concurrent smoking cessation support in the NetherlandsKoen de Nijs, Kevin Ten Haaf, Carlijn van der Aalst, et al.
International Journal of Cancer|October 4, 2023
Cost-effectiveness of risk-based low-dose computed tomography screening for lung cancer in SwitzerlandYuki Tomonaga, Koen de Nijs, Heiner C Bucher, et al.
International Journal of Cancer|March 30, 2021
Personalising lung cancer screening: An overview of risk-stratification opportunities and challengesKevin Ten Haaf, Carlijn M van der Aalst, Harry J de Koning, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 10, 2015
Baseline Characteristics and Mortality Outcomes of Control Group Participants and Eligible Non-Responders in the NELSON Lung Cancer Screening StudyUraujh Yousaf-Khan, Nanda Horeweg, Carlijn van der Aalst, et al.
Journal of the National Cancer Institute|November 9, 2017
Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the MethodologyTheodora M Ripping, Kevin Ten Haaf, André L M Verbeek, et al.
The Lancet Regional Health. Western Pacific|December 10, 2024
Targeted lung cancer screening in the age of immunotherapies and targeted therapies - an economic evaluation for AustraliaJacqueline Roseleur, Jonathan Karnon, Harry de Koning, et al.
Cancer|November 1, 2023
Assessing the impact of increasing lung screening eligibility by relaxing the maximum years-since-quit threshold: A simulation modeling studyRafael Meza, Pianpian Cao, Koen de Nijs, et al.
Pageof 8